leadf
logo-loader
viewCanntab Therapeutics Ltd

Canntab Therapeutics achieves major milestone receiving first U.S. patent for multilayer tablets

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CEO Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has secured protection for their intellectual property receiving a U.S. patent for “Modified Release Multi-Layer Tablet Cannabinoid Formulations.”

Latowsky talks about what that means for the company and moving forward and how they hope to now make a major push to monetize that IP.

Quick facts: Canntab Therapeutics Ltd

Price: 0.83 CAD

CSE:PILL
Market: CSE
Market Cap: $27.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Canntab Therapeutics hits major milestone as company makes first delivery to...

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CEO Larry Latowski and CFO Richard Goldstein joined Steve Darling from Proactive with news the company has completed its first delivery of two of five SKU's ordered by MediPharm Labs. Goldstein and Latowski tall about them taking this major step...

on 12/01/2020

2 min read